{"id":10015,"date":"2009-03-03T00:00:00","date_gmt":"2009-03-03T00:00:00","guid":{"rendered":""},"modified":"-0001-11-30T00:00:00","modified_gmt":"-0001-11-30T04:00:00","slug":"indevus-soars-on-drug-hedge-fund-news","status":"publish","type":"post","link":"https:\/\/hedgeco.net\/news\/03\/2009\/indevus-soars-on-drug-hedge-fund-news.html","title":{"rendered":"Indevus soars on drug, hedge fund news"},"content":{"rendered":"<p>Boston Business Journal &#8211; Just days after winning regulatory approval for the manufacture and marketing of its cancer therapy for bladder cancer, Indevus Pharmaceuticals Inc. <strong><span class=\"story_clink\"><strong \/><\/span><\/strong>disclosed that a North Carolina hedge fund has acquired 8.5 percent of its common stock.<\/p>\n<p>Lexington, Mass.-based Indevus made the announcements via regulatory filings late Friday and early Monday with the Securities and Exchange Commission.<strong \/><span class=\"story_clink\"><strong><br \/><\/strong><\/span><\/p>\n<p>On Friday, the company said the<span class=\"story_clink\"><strong \/><\/span> U.S. Food and Drug Administration had approved its supplemental new drug application for Valstar, a therapy that aims to treat bladder cancer through an injectable technology.<\/p>\n<p>Valstar was first approved by the FDA in 2002, however design as well as manufacturing issues have prevented Indevus from marketing the drug in the United States since 2002.<\/p>\n<p>Indevus said it intends to market Valstar during the second half of this year.<\/p>\n<p><a href=\"http:\/\/www.bizjournals.com\/boston\/stories\/2009\/03\/02\/daily1.html\" target=\"_self\">Read Complete Article<\/a> <\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston Business Journal &#8211; Just days after winning regulatory approval for the manufacture and marketing of its cancer therapy for bladder cancer, Indevus Pharmaceuticals Inc. disclosed that a North Carolina hedge fund has acquired 8.5 percent of its common stock. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[8452,8450,8455,8135,8457,8456,8459,8458,8453,8451,7132,8460,4936,6582,5080,35,21,8454],"class_list":["post-10015","post","type-post","status-publish","format-standard","hentry","category-syndicated","tag-bladder-cancer","tag-boston-business-journal","tag-cancer-therapy","tag-common-stock","tag-drug-application","tag-early-monday","tag-fda","tag-food-and-drug","tag-food-and-drug-administration","tag-indevus-pharmaceuticals-inc","tag-marketing","tag-north-carolina","tag-regulatory-approval","tag-regulatory-filings","tag-second-half","tag-securities-and-exchange","tag-securities-and-exchange-commission","tag-valstar"],"_links":{"self":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/10015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/comments?post=10015"}],"version-history":[{"count":0,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/10015\/revisions"}],"wp:attachment":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/media?parent=10015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/categories?post=10015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/tags?post=10015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}